Gilead Sciences | GILD - Interest Expense On Debt


Gilead Sciences reported $247M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
ALKERMES USD 25.92M 5.03M Jun/2026
Alnylam Pharmaceuticals USD 82.05M 12.76M Jun/2026
Amgen USD 95.64B 94.98B Jun/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 63.29M 48.34M Jun/2026
Bristol-Myers Squibb USD 403M 4M Sep/2026
Coherus Biosciences USD 2.25M 76K Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 247M 7M Jun/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
Glaxosmithkline GBP 192.73M 14.79M Mar/2026
Incyte USD 605K 23K Sep/2026
J&J USD 43M 25M Mar/2026
Merck USD 525M 46M Jun/2026
Moderna USD 10.96B 527M Jun/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 462M 119M Jun/2026
Pfizer USD 667M 4M Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR 287M 109M Jun/2026
Sarepta Therapeutics USD 21.51M 205K Jun/2026
United Therapeutics USD 2.9M 200K Jun/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025